Cellular constituents of immune escape within the tumor microenvironment
- PMID: 22721837
- PMCID: PMC6327310
- DOI: 10.1158/0008-5472.CAN-11-4094
Cellular constituents of immune escape within the tumor microenvironment
Abstract
Established tumors are complex masses that contain not only neoplastic cells but also nontransformed cellular elements such as stromal cells, the neovasculature, and the full gamut of immune cells. However, evidence suggests that, unlike cells found in lymphoid organs that productively respond to acute infections, immune cells in tumors are dysregulated and functionally impaired. Tumor masses can contain regulatory lymphocytes, myeloid-derived suppressor cells, alternatively activated macrophages, and dendritic cells. Ablation or reprogramming of this aberrant microenvironment might dramatically augment cancer therapies, and this strategy is currently being deployed in a variety of clinical trials. A better understanding of the cellular constituents of tumors and the mechanisms involved in immune evasion may help guide the next generation of innovative cancer immunotherapies.
©2012 AACR.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Figures

Similar articles
-
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.J Clin Invest. 2011 Dec;121(12):4746-57. doi: 10.1172/JCI58814. Epub 2011 Nov 7. J Clin Invest. 2011. PMID: 22056381 Free PMC article.
-
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.Sci China Life Sci. 2021 Apr;64(4):534-547. doi: 10.1007/s11427-019-1735-4. Epub 2020 Aug 17. Sci China Life Sci. 2021. PMID: 32815067 Review.
-
Combining epigenetic and immune therapy to overcome cancer resistance.Semin Cancer Biol. 2020 Oct;65:99-113. doi: 10.1016/j.semcancer.2019.12.019. Epub 2019 Dec 23. Semin Cancer Biol. 2020. PMID: 31877341 Free PMC article. Review.
-
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.Front Immunol. 2019 Dec 10;10:2876. doi: 10.3389/fimmu.2019.02876. eCollection 2019. Front Immunol. 2019. PMID: 31921140 Free PMC article. Review.
-
CCL21 Programs Immune Activity in Tumor Microenvironment.Adv Exp Med Biol. 2020;1231:67-78. doi: 10.1007/978-3-030-36667-4_7. Adv Exp Med Biol. 2020. PMID: 32060847 Review.
Cited by
-
Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.Cancers (Basel). 2024 Aug 17;16(16):2865. doi: 10.3390/cancers16162865. Cancers (Basel). 2024. PMID: 39199637 Free PMC article. Review.
-
Impact of the Tumor Microenvironment for Esophageal Tumor Development-An Opportunity for Prevention?Cancers (Basel). 2022 Apr 30;14(9):2246. doi: 10.3390/cancers14092246. Cancers (Basel). 2022. PMID: 35565378 Free PMC article. Review.
-
Multistability in the epithelial-mesenchymal transition network.BMC Bioinformatics. 2020 Feb 24;21(1):71. doi: 10.1186/s12859-020-3413-1. BMC Bioinformatics. 2020. PMID: 32093616 Free PMC article.
-
Spatial Transcriptomics: Technical Aspects of Recent Developments and Their Applications in Neuroscience and Cancer Research.Adv Sci (Weinh). 2023 Jun;10(16):e2206939. doi: 10.1002/advs.202206939. Epub 2023 Apr 7. Adv Sci (Weinh). 2023. PMID: 37026425 Free PMC article. Review.
-
Metabolic reprograming of anti-tumor immunity.Curr Opin Immunol. 2017 Jun;46:14-22. doi: 10.1016/j.coi.2017.03.011. Epub 2017 Apr 13. Curr Opin Immunol. 2017. PMID: 28412583 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources